FHD-286 + Decitabine + Venetoclax for Acute Myeloid Leukemia

(FHD-286 Trial)

This trial explores a new combination of three treatments—Decitabine, Venetoclax, and FHD-286 (an experimental treatment)—to assess their effectiveness in combating acute myeloid leukemia (AML), a type of blood cancer. It targets individuals with AML who have specific risk factors or whose condition has worsened after initial treatment. The study seeks participants diagnosed with AML, especially those facing aggressive or recurring forms of the disease that have not responded to previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.

The trial requires stopping certain medications before starting. You must stop strong CYP3A inhibitors at least 1 week before, and strong CYP3A inducers at least 2 weeks before the trial. Proton pump inhibitors must also be stopped or switched 7 days before the trial.

Research has shown that using Decitabine and Venetoclax together is generally safe for treating patients with acute myeloid leukemia (AML). Studies have found this combination to be effective and safe, particularly for older patients. One study demonstrated improved survival rates and reduced cancer when this treatment was used with other drugs.

An early study on FHD-286 examined its safety at different doses in participants with relapsed or hard-to-treat AML. While specific reports of severe side effects have not emerged, the research aimed to determine a safe dosage.

Researchers are excited about this treatment combination for acute myeloid leukemia (AML) because it introduces FHD-286, a novel compound, alongside established drugs like Decitabine and Venetoclax. FHD-286 is an epigenetic modulator, which means it can potentially alter how genes are expressed in cancer cells, possibly making them more susceptible to treatment. This approach is different from traditional chemotherapy, which targets rapidly dividing cells more broadly. By targeting the cancer cells in a new way, this combination aims to enhance treatment effectiveness and offer new hope for patients with AML.

Research has shown that combining Decitabine and Venetoclax significantly improves recovery rates in older patients with Acute Myeloid Leukemia (AML). One study found that this combination nearly doubled the rate of complete recovery compared to other treatments. In this trial, participants will receive a combination of Decitabine, Venetoclax, and FHD-286. FHD-286, a new drug under investigation, targets specific proteins in cancer cells, hindering their survival and growth. Lab studies have shown that when FHD-286 is used with Decitabine and Venetoclax, it reduces cancer and improves survival. These findings suggest this combination could effectively treat AML, especially in challenging cases.¹³⁵⁶⁷